OABI Earnings Date: Mar 3, 2027 (Estimated) — OmniAb, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is OABI's next earnings date?
OmniAb, Inc. (OABI) is expected to report Q4 2026 earnings on Wednesday, March 3, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.13 on revenue of $3.9M.
How did OABI do in its last earnings report?
In its most recent report on Oct 30, 2026 (Q3 2026), OmniAb, Inc. posted EPS of -$0.12 versus the -$0.13 estimate, a beat of 5.6%. Revenue was $4.0M against a $3.5M estimate.
How much does OABI stock move after earnings?
OABI beat EPS estimates in 3 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 13.7% (up or down) in the day after earnings.
About OmniAb, Inc.
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
🤖 AI Earnings Analysis
OmniAb’s Q3 results were mixed: revenue doubled year over year to $4M, beating estimates, but the antibody-discovery platform remains deeply loss-making, with $18M in operating losses and a -$0.12 EPS.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | Q3 2026 | -0.13 | -0.12 | +5.62% | $4.0M | ✅ Beat | — | — | — |
| 2026-08-06 | Q2 2026 | -0.12 | -0.05 | +58.33% | $13.4M | ✅ Beat | +37.50% | +53.13% | +93.30% |
| 2026-05-07 | Q1 2026 | -0.10 | -0.06 | +40.00% | $14.4M | ✅ Beat | +12.93% | +48.98% | +55.10% |
| 2026-03-04 | Q4 2025 | -0.08 | -0.11 | -37.50% | $8.4M | ❌ Miss | +10.50% | +8.01% | -14.92% |
| 2025-11-04 | Q3 2025 | -0.14 | -0.14 | +0.00% | $2.2M | ➖ Inline | -3.72% | +8.78% | +33.11% |
| 2025-08-06 | Q2 2025 | -0.15 | -0.15 | +0.00% | $3.9M | ➖ Inline | -2.59% | +6.22% | -11.40% |
| 2025-05-08 | Q1 2025 | -0.17 | -0.17 | +0.00% | $4.2M | ➖ Inline | -8.28% | -1.27% | -4.46% |
| 2025-03-18 | Q4 2024 | -0.10 | -0.12 | -20.00% | $10.8M | ❌ Miss | -20.38% | -23.51% | -44.51% |
Showing last 8 quarters.